- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 314 | GlobeNewswire (Europe) | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 281 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 292 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 339 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 272 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 311 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 308 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 247 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 454 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 119,14 | -0,38 % | Zwei Dividendenwerte im Fokus: Warum ein Profi-Investor im August bei Gilead und American Tower zugreift | Gilead Sciences und American Tower rücken als Dividendenwerte in den Fokus, weil beide laut einer Analyse auf Seeking Alpha für den August aufgestockt werden. Im Zentrum stehen ein attraktives Chance-Risiko-Verhältnis... ► Artikel lesen | |
| ABBVIE | 216,10 | +0,23 % | Warum Lillys 3,8-Milliarden-Dollar-Deal den Psychedelika-Sektor verändert - und warum Emyria jetzt in den Fokus rücken könnte | ||
| ABBOTT LABORATORIES | 96,32 | +0,15 % | Can Abbott Laboratories (ABT)'s Lingo Partnership With Alphabet (GOOG) Unlock a New Era of AI-Powered Health? | ||
| INNOCAN PHARMA | 1,445 | +4,33 % | Innovative Pharma-Strategien: Warum InnoCan auf langfristiges Wachstum setzt | ||
| SCHOTT PHARMA | 21,950 | +0,69 % | Ihre wichtigsten Termine: Tui, Bechtle, Jenoptik, Douglas, Eon und Freenet mit frischen Zahlen-Updates | © Foto: Clara Margais/dpa/dpa-tmnGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 79,40 | +0,25 % | $100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today | ||
| ASSEMBLY BIOSCIENCES | 28,250 | -0,70 % | Assembly Biosciences +11%: Der Mega-Blockbuster und der schweigende Partner | Assembly Biosciences steht vor einer weiteren Neubewertung. Der gestrige Quartalsbericht des US-Biotechunternehmens enthält auf den ersten Blick vor allem eine operative Nachricht: Gilead Sciences hat... ► Artikel lesen | |
| PENTIXAPHARM | 1,890 | -0,79 % | Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen | Original-Research: Pentixapharm Holding AG - von BankM AG
10.08.2026 / 11:26 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,795 | +0,63 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 183,50 | -0,70 % | If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today | ||
| MEDPACE | 500,00 | 0,00 % | If You Invested $100 In Medpace Holdings Stock 5 Years Ago, You Would Have This Much Today | ||
| ZEALAND PHARMA | 42,930 | +0,37 % | Zealand Pharma A/S: Zealand Pharma Announces Financial Results for the First Half of 2026 | Company announcement - No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a... ► Artikel lesen | |
| UNITED THERAPEUTICS | 433,80 | +0,39 % | United Therapeutics Corp Bottom Line Climbs In Q2 | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) announced a profit for its second quarter that Increased, from the same period last yearThe company's earnings totaled $333.0 million,... ► Artikel lesen | |
| UCB | 212,60 | -0,05 % | UCB H1 Profit Surges On Strong Revenue Growth; Raises Outlook | BRUSSELS (dpa-AFX) - UCB S.A. (UCBJY), a Belgium-based biopharmaceutical company, on Thursday reported sharply higher first-half profit, supported by strong revenue growth.Profit attributable... ► Artikel lesen | |
| JAGUAR HEALTH | 0,890 | -2,84 % | Jaguar Health, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,71 % bei einem Aktienkurs von 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.